0H7R.L - Abeona Therapeutics Inc.

LSE - LSE Delayed price. Currency in USD

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019
United States
646 813 4701

Full-time employees57

Key executives

NameTitlePayExercisedYear born
Dr. Vishwas Seshadri M.B.A., Ph.D.Pres, CEO & Director1.02MN/A1976
Mr. Joseph Walter VazzanoChief Financial Officer655.17kN/A1985
Dr. Brendan M. O'Malley J.D., Ph.D.Sr. VP & Gen. Counsel699.13kN/A1969
Mr. Brian Kevany Ph.D.VP, CTO & Head of ResearchN/AN/AN/A
Mr. Gregory GinVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Alison HardgroveVP of HRN/AN/AN/A
Mr. Jon VossVP & Head of QualityN/AN/A1960
Mr. Dmitriy Grachev M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

Corporate governance

Abeona Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.